Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
US11059906B2 · kind B2 · utility
0Cited by
13References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2014 |
| Grant date | Jul 13, 2021 |
| Priority date | — |
| Expiry date | May 23, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fusion proteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.